Vnitřní lékařství 2/2021

PŘEHLEDOVÉ ČLÁNKY Glukagon v léčbě hypoglykemie – novinky 108 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(2): 103–108 / www.casopisvnitrnilekarstvi.cz LITERATURA 1. Schovánek J, Cibíčková L, Čtvrtlík F et al. Diferenciální diagnostika hypoglykemie. Vni- tr Lek 2020; 66(2): 129–133. 2. Brož J, Urbanová J.Rámcový pohled na epidemiologii hypoglykemie u diabetes melli- tus 1. a 2. typu. Vnitr Lek 2019; 65(4): 55–60. 3. Brož J, Urbanová J, Nunes MA. Současný pohled na léčbu hypoglykemie. Vnitr Lek 2019; 65(4): 61–65. 4. Brož J, Halciaková K, Janíčková Žďárská D et al. Zdravotní způsobilost k řízení motoro- vých vozidel a diabetes mellitus – legislativní změny v r. 2018 a souhrn zdravotních aspek- tů, Vnitr Lek 2019; 65(4): 82–86. 5. Brunerová L, Urbanová J, Brož J, Hypoglykemie jako symptom adrenální dysfunkce u pacientů s diabetes mellitus – vzácná, ale reálná situace. Vnitr Lek 2019; 65(4): 69–71. 6. Tuháčková M, Urbanová J, Brunerová J et al. Alkohol a riziko hypoglykemie. Vnitr Lek 2019; 65(4): 72–75. 7. [International Hypoglycaemia Study Group]. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position State- ment of the American Diabetes Association and the European Association for the Stu- dy of Diabetes. Diabetes Care 2017; 40(1): 155–157. Dostupné z DOI: <http://dx.doi. org/10.2337/dc16–2215>. 8. Seaquist ER, Anderson J, Childs B et al. Hypoglycemia and Diabetes: A Report of a Work- group of the American Diabetes Association and The Endocrine Society. Diabetes Care 2013; 36(5): 1384–1395. 9. Ahrén B. Glucagon-Early breakthroughs and recent discoveries. Peptides. 2015;67:74- 81. doi:10.1016/j.peptides.2015. 03. 011 10. Scott RV, Bloom SR. Problem or solution: The strange story of glucagon. Peptides. 2018;100:36-41. doi:10.1016/j.peptides.2017. 11. 013 11. Rix I, Nexøe‑Larsen C, Bergmann NC, et al. Glucagon Physiology. [Updated 2019 Jul 16]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279127/ 12. Langerhansovy ostrůvky 526-530 in Kittnar O a kol. Lékařská fyziologie Praha, Grada Publishing, a. s. 2020, ISBN 978-80-247-9528-7. 13. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose‑dependent insulinot- ropic polypeptide: a bifunctional glucose‑dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 3103–3109. 14. Hawkes CP, De Leon DD, Rickels MR. Novel Preparations of Glucagon for the Preventi- on and Treatment of Hypoglycemia. Curr Diab Rep. 2019;19(10):97. Published 2019 Sep 6. doi:10.1007/s11892-019-1216-4 15. Demirbilek H, Hussain K. Congenital Hyperinsulinism: Diagnosis and Treatment Up- date. J Clin Res Pediatr Endocrinol. 2017; 9(Suppl 2): 69–87. doi:10.4274/jcrpe.2017.S007. 16. Mulla CM, Zavitsanou S, Laguna Sanz AJ, et al. A Randomized, Placebo‑Controlled Double‑Blind Trial of a Closed‑Loop Glucagon System for Postbariatric Hypoglycemia. J Clin Endocrinol Metab. 2020; 105(4): e1260–e1271. doi:10.1210/clinem/dgz197. 17. Peters TM, Haidar A. Dual‑hormone artificial pancreas: benefits and limitations com- pared with single‑hormone systems. Diabet Med. 2018; 35(4): 450–459. doi:10.1111/ dme.13581. 18. Bi, Y., Atwal, T. & Vege, S.S. Drug Therapy for Acute Pancreatitis. Curr Treat Options Gastro 13, 354–368 (2015). https://doi‑org.ezproxy.is.cuni.cz/10.1007/s11938-015-0058-7. 19. Vindal A, Chander J, Lal P, Mahendra B. Comparison between intraoperative cholangiogra- phy and choledochoscopy for ductal clearance in laparoscopic CBD exploration: a prospec- tive randomized study. Surg Endosc. 2015; 29(5): 1030–1038. doi:10.1007/s00464-014-3766-5. 20. Greben SE, Schulman JL. The effect of glucagon on the blood glucose level and the clini- cal state in the presence of marked insulin hypoglycemia. J Clin Invest. 1957; 36(1 Part 1): 74– 80. doi:10.1172/JCI103412. 21. Ebers DW, Meckel BR. Use of glucagon to terminate insulin reactions in diabetic chil- dren. Nebr State Med J. 1958; 43(2): 56–57. 22. Elrick H, Witten TA, Arai Y. (1958). Glucagon Treatment of Insulin Reactions. New England Journal of Medicine, 258(10), 476–480. doi:10.1056/nejm195803062581005. 23. Wiethop BV, Cryer PE. Alanine and Terbutaline in Treatment of Hypoglycemia in IDDM. Diabetes Care 1993; 16(8): 1131–1136. 24. Boido A, Ceriani V, Pontiroli AE. (2014). Glucagon for hypoglycemic episodes in insulin­ ‑treated diabetic patients: a systematic review and meta‑analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetologica, 52(2), 405–412. doi:10.1007/s00592-014-0665-0 25. http://cmp‑manual.wbs.cz/-_leky_-/glucagen-1-mg‑hypokit‑spc.pdf. 26. Hall‑Boyer K, Zaloga GP, Chernow B. Glucagon: hormone or therapeutic agent? Crit Care Med 1974; 12(7): 584–589. 27. 23. Lee H, Hosein EA. Chronic alcohol feeding and its withdrawal on the structure and function of the rat liver plasma membrane: a study with 125I‑labelled glucagon binding as a metabolic probe. Can J Physiol Pharmacol 1982; 60(9): 1171–1176. 28. American Medical Association. Division of Drugs and Toxicology. Drug evaluations an- nual 1994. American Medical Association: Chicago 1993. ISBN 08997060299780899706023. 29. Eli Lilly and Company. http://cmp‑manual.wbs.cz/-_leky_-/glucagen-1-mg‑hypokit‑spc. pdfGlucagon Emergency Kit. http://www.lillyglucagon.com. Accessed October 29, 2018. 30. Yanai O, Phillip M, Harman I et al. IDDM patients‘ opinions on the use of glucagon emer- gency kit in severe episodes of hypoglycaemia. Pract Diab Int 1997; 14: 40–42. doi:10.1002/ pdi.1960140204. 31. Mühlhauser I, Berger M, Sonnenberg G, Koch J, Jörgens V, Schernthaner G, Scholz V, Pä- dagogin D. Incidence and management of severe hypoglycemia in 434 adults with insulin­ ‑dependent diabetes mellitus. Diabetes Care. 1985; 8(3): 268–273. doi: 10.2337/diacare.8. 3. 268. 32. Yale JF, Dulude H, EgethM et al. Faster use and fewer failures with needle‑free nasal guca- gon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther 2017; 19(7): 423–432. Dostupné z DOI: http://dx.doi.org/10.1089/dia.2016.0460. 33. Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Effects of common cold and concomi- tant administration of nasal decongestant on the pharmacokinetics and pharmacody- namics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab. 2018; 20(3): 646–653. 34. Guzman CB, Dulude H, Piche C et al. Effects of common cold and concomitant ad- ministration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab.2018; 20: 646–653. 35. Rickels MR, Ruedy KJ, Foster NC et al. Intranasal glucagon for treatment of insulin­ ‑induced hypoglycemia in adults with type 1 diabetes:a randomized crossover noninfe- riority study. Diabetes Care. 2016; 39: 264–270. 36. Suico J, Hövelmann U, Zhang S et al. Nasal glucagon: a viable alternative to treat insulin­ ‑induced hypoglycaemia in adults with type 1 diabetes. Diabetologia. 2018; 61(Suppl 1): 77–78. 37. Seaquist ER, Dulude H, Zhang XM et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‑world setting. Diabetes Obes Metab. 2018; 20: 1316–1320. 38. Castle JR, Youssef JE, BraniganD, Newswanger B, Strange P, Cummins M, Shi L, Prestrelski S. Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid StableGlucagon Versus Lyo- philizedGlucagon in Type 1Diabetes Subjects.J Diabetes Sci Technol. 2016 Sep; 10(5): 1101–1107. 39. Xeris Pharmaceuticals. GVOKE US Prescribing Information. 2019. https://www.accessda- ta.fda.gov/drugsatfda_docs/label/2019/ 212097s000lbl.pdf. 40. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usa- bility and validation studies of a glucagon autoinjector in a simulated severe hypoglyce- mia rescue situation. Diabetes Technol Ther. 2019; 21(9): 522–530. 41. Cummins M, Andre A, Christiansen MP, Newswanger B, Prestrelski S, Junaidi MK. An assessment of usability and drug preparation time for a ready‑to‑use liquid glucagon pen. J Diabetes Sci Technol. 2019; 13: 293–409. 42. Christiansen MP, Cummins M, Prestrelski S, Junaidi MK. A phase 3 comparison of a ready­ ‑to‑use liquid glucagon rescue pen to glucagon emergency kit for the symptomatic relief of severe hypoglycemia. J Diabetes Sci Technol. 2019; 13: 293–409. 43. Beato‑Víbora PI, Arroyo‑Díez FJ. New uses and formulations of glucagon for hypo- glycaemia. Drugs Context. 2019; 8: 212599. Published 2019 Jul 30. doi:10.7573/dic.212599. 44. Laffel LM, Limbert C, Phelan H, Virmani A, Wood J, Hofer SE. ISPAD Clinical Practice Consensus Guidelines 2018: Sick day management in children and adolescents with dia- betes. Pediatr Diabetes. 2018; 19 Suppl 27(): 193–204. 45. Ranjan A, Schmidt S, Madsbad S, Holst JJ, Nørgaard K. Effects of subcutaneous, low­ ‑dose glucagon on insulin‑induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. Diabetes, Obes Metab. 2016; 18(4): 410–418. doi: 10.1111/dom.12627. 46. Haymond MW, Redondo MJ, McKay S et al. Nonaqueous, Mini‑Dose Glucagon for Tre- atment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose‑Seeking Study. Dia- betes Care. 2016; 39(3): 465–468. doi:10.2337/dc15-2124. 47. Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, Cummins MJ, News- wanger B, Riddell MC, T1D Exchange Mini‑Dose Glucagon Exercise Study Group. Mini‑Dose Glucagon as a Novel Approach to Prevent Exercise‑Induced Hypoglycemia in Type 1 Dia- betes.Diabetes Care. 2018; 41(9): 1909–1916. 48. Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Møller DV, Heise T. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.Diabetes Care. 2018; 41(3): 531–537. 49. Pieber TR, HoevelmannU, Willard J et al. Phase 3 results for dasiglucagon as a fast and effec- tive treatment for severe hypoglycemia. Presented at: AmericanDiabetes Association 79 th Sci- entific Sessions; June 7–11, 2019; San Francisco, CA. Oral Presentation 286-OR. 50. HövelmannU, OlsenMB, MouritzenU, LamersD, KronshageB, Heise T. Lowdoses of dasigluca- gon consistently increaseplasmaglucose levels fromhypoglycaemia andeuglycaemia inpeople with type 1 diabetesmellitus. DiabetesObesMetab. 2019; 21(3): 601–610. doi:10.1111/dom.13562. 51. Ranson A, Hövelmann U, Seroussi C, Lamers D, Correia J, Zijlstra E et al. Biochaperone glu- cagon, a stable ready‑to‑use liquid glucagon formulation enabled by biochaperone techno- logy, is well tolerated and quickly restores euglycemia after insulin‑induced hypoglycemia Advanced Technologies & Treatment for Diabetes; 20–23bruary 2019; Berlin, Germany: 2019. 52. Glezer S, Hovelmann U, Teng S, Lamers D, Odoul M, Correia J et al. BioChaperone gluca- gon (BCG), a stable ready‑to‑use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin‑induced hypoglycemia. Diabetes. 2018; 67(Supplement 1): 305–OR. 10.2337/db18-305-OR.